8-K: Precision BioSciences Announces $40 Million Public Offering of Common Stock and Warrants

Precision BioSciences has announced a public offering to sell 2.5 million shares of common stock and accompanying warrants, aiming to raise $40 million before expenses.

Summary

• Precision BioSciences has entered into an underwriting agreement for a public offering of 2.5 million shares of common stock and accompanying warrants.
• The combined offering price is $16.00 per share and warrant, with the warrants having an exercise price of $20.00 per share.
• The company anticipates gross proceeds of $40 million from the offering, before deducting underwriting discounts and commissions.
• Net proceeds are estimated to be approximately $37.1 million after deducting underwriting discounts, commissions, and estimated offering expenses.
• The company intends to use the net proceeds to fund ongoing and planned research and development, working capital, and other general corporate purposes.
• The underwriter has a 30-day option to purchase an additional 375,000 shares and warrants.
• The offering is expected to close on or about March 5, 2024, subject to customary closing conditions.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the offering dilutes existing shareholders, it provides necessary capital for the company's research and development efforts, which is crucial for its long-term growth. The participation of leading life sciences investors is also a positive sign.

Positives

• The offering is expected to provide Precision BioSciences with approximately $37.1 million in net proceeds.
• The funds will be used to support ongoing and planned research and development, as well as for working capital and general corporate purposes.
• The participation of leading life sciences investors indicates confidence in the company's prospects.
• The underwriter's option to purchase additional shares could lead to further capital infusion.

Negatives

• The offering will dilute existing shareholders' ownership.
• The warrants, if exercised, could further dilute the stock.
• The company will incur underwriting discounts, commissions, and offering expenses, reducing the net proceeds.

Risks

• The company's business is subject to substantial risks and uncertainties.
• The offering is subject to customary closing conditions and may not close as expected.
• Market conditions could impact the success of the offering.
• The company's future performance is subject to risks identified in its SEC filings.

Future Outlook

The company intends to use the net proceeds of the offering to fund ongoing and planned research and development, and for working capital and other general corporate purposes.

Management Comments

• Precision BioSciences is an advanced gene editing company dedicated to improving life with its novel and proprietary ARCUS genome editing platform.
• The company's pipeline is comprised of in vivo gene editing candidates designed to deliver lasting cures for the broadest range of genetic and infectious diseases where no adequate treatments exist.

Industry Context

This offering is part of a broader trend of biotechnology companies raising capital to fund research and development, particularly in the gene editing space, which is attracting significant investor interest due to its potential for transformative therapies.

Comparison to Industry Standards

• The offering structure, combining common stock and warrants, is a common approach for biotech companies seeking capital.
• The pricing and terms of the warrants are within the typical range for similar offerings in the biotech sector.
• The use of proceeds for research and development is consistent with industry norms for companies in this stage of development.
• Comparable companies that have recently raised capital include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, all of which are also focused on gene editing technologies.

Stakeholder Impact

• Shareholders will experience dilution of their ownership due to the issuance of new shares.
• The company will have additional capital to fund its operations and research, which could benefit employees and other stakeholders.
• The offering could lead to increased investor interest and potentially a higher valuation for the company in the long term.
• The company's customers and partners may benefit from the company's ability to advance its research and development programs.

Next Steps

• The company will proceed with the closing of the offering, expected on or about March 5, 2024.
• The company will use the net proceeds to fund ongoing and planned research and development, working capital, and other general corporate purposes.
• The company will continue to develop its ARCUS gene editing platform and advance its pipeline of in vivo gene editing candidates.

Key Dates

Keywords

public offering, common stock, warrants, gene editing, ARCUS platform, biotechnology, capital raise, research and development, Precision BioSciences, Guggenheim Securities